Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The enterprise will focus on developing targeted therapies for a specific family of blood cancers.

Professor Adam Mead (left) and Professor Beth Psaila wearing labcoats and surrounded by lab equipment. © MRC WIMM
Professor Adam Mead (left) and Professor Beth Psaila (right) launch their new spin-out company, Alethiomics.

This week sees the launch of Alethiomics, a drug-discovery company co-founded by Professor Adam Mead and Professor Beth Psaila with support from Oxford University Innovation. Alethiomics aims to apply innovations in single-cell multi-omic analysis to the development of novel therapeutics for myeloproliferative neoplasms (MPNs).

MPNs are a group of chronic blood cancers that begin with mutations occurring in cancer stem cells in the bone marrow. While currently available treatments can relieve symptoms, they do not tackle the underlying disease drivers meaning patients have poor prognosis.

Identifying new drug targets within these mutant cells is critical to developing targeted and effective therapies. The founders have pioneered the use of single-cell multi-omics approaches to better understand the biology of MPNs and to discover novel molecular targets as the basis for drug discovery. They have also developed bespoke platforms for target validation to accelerate successful translation to the clinic. ‘The Alethiomics TARGET-seq platform simultaneously detects DNA mutations, the RNA transcriptome and cell surface proteins from individual cells to provide a holistic understanding of pathologies and more intelligent target identification’ says Professor Mead co-founder of Alethiomics and leader of the Haematopoietic Stem Cell Biology Group at the MRC Molecular Haematology Unit in the Radcliffe Department of Medicine.

Below is a video from the Oxford Centre For Haematology, explaining the work developed by Prof. Psaila and Prof. Mead.

The spin-out has received £6m of seed financing from Oxford Science Enterprises. ‘We have been tremendously impressed by the unparalleled expertise in haematological cancer of Prof. Mead and Prof. Psaila, and their passion to bring new therapies to the clinic to help benefit patients.’ Says Dr Claire Brown, Life Sciences Partner at Oxford Science Enterprises. ’We look forward to building on their foundational discoveries and to developing clinical programmes therapies that deliver on the early promise of the technology.’

‘We are really excited to have founded Alethiomics’ says Professor Beth Psaila, Alethiomics co-founder and leader of the Normal and Malignant Megakaryocyte and Platelet Biology Group at the MRC Molecular Haematology Unit. ‘Alethiomics…will enable us to translate our breakthrough discoveries in novel target identification into precision medicines to improve the lifespan and quality of life for the patients we care for in the clinic.’

Research underlying this TARGET-seq platform was highlighted in a plenary session delivered at the  American Society of Hematology (ASH) annual meeting on 12th December 2021

Similar stories

T cell Immunotherapy animation launched

A new animation explores work by the Chakraverty Group, Vyas Group, and Professor Borrow from the Jenner Institute.

New study reveals role of lymphatic system in bone healing

It was previously assumed that bones lacked lymphatic vessels, but new research from the Kusumbe Group published in Cell not only locates them within bone tissue, but demonstrates their role in bone and blood cell regeneration and reveals changes associated with aging.

Irene Roberts delivers Ham-Wasserman Lecture

Presented at the American Society of Hematology Annual Meeting, the award and lectureship recognises individuals from outside the United States who have made significant contributions to Haematology.

Anjali Kusumbe receives Women in Cell Biology Early Career Medal

Founded in 2015 to mark the 50th anniversity of the founding of the British Society for Cell Biology, the award recognises outstanding early career biologists.

Asger Jakobsen receives ASH-BSH Abstract Achievement Award

Dr Jakobsen, a Clinical Research Fellow and DPhil student from the Vyas Group has received the award from the American Society of Hematology and the British Society of Haematology.